<DOC>
	<DOCNO>NCT00737529</DOCNO>
	<brief_summary>To evaluate safety efficacy Lenalidomide ( Revlimid ( R ) ) subject mantle cell lymphoma relapse , progress refractory bortezomib .</brief_summary>
	<brief_title>A Study Determine Efficacy Safety Lenalidomide Patients With Mantle Cell NHL Who Have Relapsed Progressed After Treatment With Bortezomib Are Refractory Bortezomib . The `` EMERGE '' Trial</brief_title>
	<detailed_description>Follow phase continue either 100 % patient die , lose follow withdrawn consent maximum 4 year last patient enrol , whichever come first . All efficacy safety endpoint updated time . In unlikely event study close patient still respond treatment time , Celgene discuss treat physician option provide treatment patient study closure line local regulation . Follow second primary malignancy OS continue 100 % patient die , lose follow , withdrawn consent , maximum 5 year last patient enrol , whichever come first .</detailed_description>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Biopsy proven mantle cell lymphoma Patients must document relapse , refractory PD treatment bortezomib Must measureable disease cross sectional imaging CT Eastern Cooperative Oncology Group ( ECOG ) performance score 0,1 2 Willing follow pregnancy precaution Any follow laboratory abnormality Absolute neutrophil count ( ANC ) &lt; 1,500 cells/mm3 ( 1.5 x 109/L ) Platelet count &lt; 60,000/mm3 ( 60 x 109/L ) Serum aspartate transaminase/Serum glutamic oxaloacetic transaminase ( AST/SGOT ) alanine transaminase/Serum glutamic pyruvic transaminase ( ALT/SGPT ) &gt; 3.0 x upper limit normal ( ULN ) , except patient document liver involvement lymphoma . Serum total bilirubin &gt; 1.5 x ULN , except case Gilbert 's Syndrome document liver involvement lymphoma . Calculated creatinine clearance ( CockcroftGault formula ) &lt; 30 mL /min Patients candidate high dose chemotherapy/allogeneic stem cell transplant eligible History active central nervous system ( CNS ) lymphoma within previous 3 month Subjects willing unable take deep vein thrombosis ( DVT ) prophylaxis Prior history malignancy , MCL , unless patient free disease â‰¥ 3 year Positive Human immunodeficiency virus ( HIV ) active Hepatitis B C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Mantle Cell Lymphoma</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>CC-5013</keyword>
	<keyword>Revlimid</keyword>
	<keyword>Lenalidomide</keyword>
</DOC>